Overcoming implementation challenges of personalized cancer therapy

Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

(2012) Taru Muranen et al.   CANCER CELL

Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks

(2012) Michael J. Lee et al.   CELL

An emerging toolkit for targeted cancer therapies

(2012) G. B. Mills   GENOME RESEARCH

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical and Economic Aspects of KRAS Mutational Status as Predictor for Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer Patients

(2012) Robert Königsberg et al.   ONCOLOGY

Whole Cancer Genome Sequencing by Next-Generation Methods

(2011) Jeffrey S. Ross et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials

(2011) Raoul Tibes et al.   CANCER

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective

(2011) P. R. Blank et al.   CLINICAL CANCER RESEARCH

Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors

(2011) Naoki Niikura et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

(2011) A. M. Gonzalez-Angulo et al.   MOLECULAR CANCER THERAPEUTICS

Tumour evolution inferred by single-cell sequencing

(2011) Nicholas Navin et al.   NATURE

Targeting the missing links for cancer therapy

(2011) Kornelia Polyak et al.   NATURE MEDICINE

The ethical use of mandatory research biopsies

(2011) Erin M. Olson et al.   Nature Reviews Clinical Oncology

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience

(2011) H. El-Osta et al.   ONCOLOGIST

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

The BATTLE Trial: Personalizing Therapy for Lung Cancer

(2011) Edward S. Kim et al.   Cancer Discovery

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

(2010) Ruth E. Board et al.   BREAST CANCER RESEARCH AND TREATMENT

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer

(2010) J. Dupont Jensen et al.   CLINICAL CANCER RESEARCH

Confronting real time ethical, legal, and social issues in the Electronic Medical Records and Genomics (eMERGE) Consortium

(2010) Ellen Wright Clayton et al.   GENETICS IN MEDICINE

Selecting Systemic Cancer Therapy One Patient at a Time: Is There a Role for Molecular Profiling of Individual Patients With Advanced Solid Tumors?

(2010) James H. Doroshow   JOURNAL OF CLINICAL ONCOLOGY

Future of Personalized Medicine in Oncology: A Systems Biology Approach

(2010) Ana Maria Gonzalez-Angulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

(2010) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032

(2010) Jonas N Søndergaard et al.   Journal of Translational Medicine

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

(2010) Shinichi Yachida et al.   NATURE

Social Networkers' Attitudes Toward Direct-to-Consumer Personal Genome Testing

(2009) Amy L. McGuire et al.   AMERICAN JOURNAL OF BIOETHICS

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer

(2009) C. Liedtke et al.   ANNALS OF ONCOLOGY

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

(2009) R E Board et al.   BRITISH JOURNAL OF CANCER

Effective Incorporation of Biomarkers into Phase II Trials

(2009) L. M. McShane et al.   CLINICAL CANCER RESEARCH

Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

(2009) E. A. Mittendorf et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Evidence for Common Clonal Origin of Multifocal Lung Cancers

(2009) Xiaoyan Wang et al.   JNCI-Journal of the National Cancer Institute

The cancer genome

(2009) Michael R. Stratton et al.   NATURE

Computational methods for discovering structural variation with next-generation sequencing

(2009) Paul Medvedev et al.   NATURE METHODS

Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples

(2009) Laura E. MacConaill et al.   PLoS One

Biomarkers In Early Clinical Trials: the Committed and the Skeptics

(2008) U. Banerji et al.   CLINICAL CANCER RESEARCH

Detection of Mutations inEGFRin Circulating Lung-Cancer Cells

(2008) Shyamala Maheswaran et al.   NEW ENGLAND JOURNAL OF MEDICINE

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE